[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TLR2

Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein Cytoplasmic vesicle, phagosome membrane Single-pass type I membrane protein Membrane raft Note=Does not reside in lipid rafts before stimulation but accumulates increasingly in the raft upon the presence of the microbial ligand. In response to diacylated lipoproteins, TLR2:TLR6 heterodimers are recruited in lipid rafts, this recruitment determines the intracellular targeting to the Golgi apparatus. Triacylated lipoproteins induce the same mechanism for TLR2:TLR1 heterodimers.
Domain PF13855 Leucine rich repeat
PF01463 Leucine rich repeat C-terminal domain
PF01582 TIR domain
Function

Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:21078852, PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins (PubMed:10426995, PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4 (PubMed:16622205). MAPK activation in response to bacterial peptidoglycan also occurs via this receptor (PubMed:16622205). Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PstS1, some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36); the lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen (PubMed:19362712). M.tuberculosis HSP70 (dnaK) but not HSP65 (groEL-2) acts via this protein to stimulate NF-kappa-B expression (PubMed:15809303). Recognizes M.tuberculosis major T-antigen EsxA (ESAT-6) which inhibits downstream MYD88-dependent signaling (shown in mouse) (By similarity). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides (PubMed:16880211). Required for normal uptake of M.tuberculosis, a process that is inhibited by M.tuberculosis LppM (By similarity).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001666 response to hypoxia
GO:0001774 microglial cell activation
GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002274 myeloid leukocyte activation
GO:0002367 cytokine production involved in immune response
GO:0002374 cytokine secretion involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006606 protein import into nucleus
GO:0006631 fatty acid metabolic process
GO:0006690 icosanoid metabolic process
GO:0006691 leukotriene metabolic process
GO:0006913 nucleocytoplasmic transport
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007252 I-kappaB phosphorylation
GO:0007272 ensheathment of neurons
GO:0008366 axon ensheathment
GO:0009306 protein secretion
GO:0009595 detection of biotic stimulus
GO:0009636 response to toxic substance
GO:0010001 glial cell differentiation
GO:0010720 positive regulation of cell development
GO:0010927 cellular component assembly involved in morphogenesis
GO:0014003 oligodendrocyte development
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0016045 detection of bacterium
GO:0016055 Wnt signaling pathway
GO:0017038 protein import
GO:0021782 glial cell development
GO:0022010 central nervous system myelination
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0031349 positive regulation of defense response
GO:0031503 protein complex localization
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032288 myelin assembly
GO:0032289 central nervous system myelin formation
GO:0032291 axon ensheathment in central nervous system
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032490 detection of molecule of bacterial origin
GO:0032493 response to bacterial lipoprotein
GO:0032496 response to lipopolysaccharide
GO:0032570 response to progesterone
GO:0032602 chemokine production
GO:0032606 type I interferon production
GO:0032608 interferon-beta production
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032621 interleukin-18 production
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0032640 tumor necrosis factor production
GO:0032642 regulation of chemokine production
GO:0032648 regulation of interferon-beta production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032661 regulation of interleukin-18 production
GO:0032675 regulation of interleukin-6 production
GO:0032677 regulation of interleukin-8 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032722 positive regulation of chemokine production
GO:0032728 positive regulation of interferon-beta production
GO:0032733 positive regulation of interleukin-10 production
GO:0032735 positive regulation of interleukin-12 production
GO:0032741 positive regulation of interleukin-18 production
GO:0032755 positive regulation of interleukin-6 production
GO:0032757 positive regulation of interleukin-8 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032868 response to insulin
GO:0033157 regulation of intracellular protein transport
GO:0033559 unsaturated fatty acid metabolic process
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034123 positive regulation of toll-like receptor signaling pathway
GO:0034134 toll-like receptor 2 signaling pathway
GO:0034504 protein localization to nucleus
GO:0036293 response to decreased oxygen levels
GO:0038123 toll-like receptor TLR1:TLR2 signaling pathway
GO:0038124 toll-like receptor TLR6:TLR2 signaling pathway
GO:0042063 gliogenesis
GO:0042116 macrophage activation
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042346 positive regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042494 detection of bacterial lipoprotein
GO:0042495 detection of triacyl bacterial lipopeptide
GO:0042496 detection of diacyl bacterial lipopeptide
GO:0042552 myelination
GO:0042742 defense response to bacterium
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043434 response to peptide hormone
GO:0044744 protein targeting to nucleus
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045685 regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0046209 nitric oxide metabolic process
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048545 response to steroid hormone
GO:0048709 oligodendrocyte differentiation
GO:0048713 regulation of oligodendrocyte differentiation
GO:0048714 positive regulation of oligodendrocyte differentiation
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050830 defense response to Gram-positive bacterium
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051767 nitric-oxide synthase biosynthetic process
GO:0051769 regulation of nitric-oxide synthase biosynthetic process
GO:0051770 positive regulation of nitric-oxide synthase biosynthetic process
GO:0051962 positive regulation of nervous system development
GO:0070339 response to bacterial lipopeptide
GO:0070340 detection of bacterial lipopeptide
GO:0070391 response to lipoteichoic acid
GO:0070482 response to oxygen levels
GO:0070542 response to fatty acid
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071220 cellular response to bacterial lipoprotein
GO:0071221 cellular response to bacterial lipopeptide
GO:0071222 cellular response to lipopolysaccharide
GO:0071223 cellular response to lipoteichoic acid
GO:0071396 cellular response to lipid
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071724 response to diacyl bacterial lipopeptide
GO:0071725 response to triacyl bacterial lipopeptide
GO:0071726 cellular response to diacyl bacterial lipopeptide
GO:0071727 cellular response to triacyl bacterial lipopeptide
GO:0072593 reactive oxygen species metabolic process
GO:0090316 positive regulation of intracellular protein transport
GO:0098542 defense response to other organism
GO:0098543 detection of other organism
GO:0098581 detection of external biotic stimulus
GO:0198738 cell-cell signaling by wnt
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901652 response to peptide
GO:1901654 response to ketone
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0001530 lipopolysaccharide binding
GO:0001875 lipopolysaccharide receptor activity
GO:0005539 glycosaminoglycan binding
GO:0008329 signaling pattern recognition receptor activity
GO:0033218 amide binding
GO:0035325 Toll-like receptor binding
GO:0038187 pattern recognition receptor activity
GO:0042277 peptide binding
GO:0042497 triacyl lipopeptide binding
GO:0042834 peptidoglycan binding
GO:0046982 protein heterodimerization activity
GO:0071723 lipopeptide binding
Cellular Component GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030670 phagocytic vesicle membrane
GO:0035354 Toll-like receptor 1-Toll-like receptor 2 protein complex
GO:0043235 receptor complex
GO:0044297 cell body
GO:0045121 membrane raft
GO:0045335 phagocytic vesicle
GO:0098589 membrane region
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04151 PI3K-Akt signaling pathway
hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-6803157: Antimicrobial peptides
R-HSA-1461957: Beta defensins
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1461973: Defensins
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-1236974: ER-Phagosome pathway
R-HSA-5603041: IRAK4 deficiency (TLR2/4)
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-5602498: MyD88 deficiency (TLR2/4)
R-HSA-166058: MyD88
R-HSA-6798695: Neutrophil degranulation
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TLR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TLR2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26598503Breast Carcinoma; Lung Carcinoma; Ovarian CarcinomaInhibit immunity (T cell function)Exosomes, via heat shock protein 70 (HSP70) expressed in their membrane, are able to interact with the toll-like receptor 2 (TLR2) on myeloid-derived suppressive cells (MDSCs), thereby activating them.
25765738MelanomaPromote immunity (infiltration)TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. CXCL10 has been implicated as a critical chemokine supporting T-cell infiltration into the TME.
25600646Hepatocellular CarcinomaPromote immunity (T cell function)TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression.
23098072Pancreatic carcinomaPromote immunity; immnuotherapy targetTo develop targeted agents for cancer imaging and therapy, we designed, synthesized, and characterized 13 novel, fully synthetic high affinity TLR2 agonists.?After conjugation of near-infrared dye to 10, agonist activity (EC(50) = 34 nM) and binding affinity (K(i) = 11 nM) were retained in 13. Fluorescence signal was present in TLR2 expressing pancreatic tumor xenografts 24 h after injection of 13, while an excess of unlabeled ligand blocked 13 from binding to the tumor, resulting in significantly decreased signal (p < 0.001) demonstrating in vivo selectivity.
24799523LymphomaPromote immunityWe treated B-cell lymphoma cells with the TLR1/2 agonist Pam3CSK4 and the genotoxic anticancer agent 1-β-D-arabinofuranosylcytosine (Ara-C). The treatment of B-cell lymphoma cells with the TLR1/2 agonist Pam3CSK4 enhanced the anticancer effects of the genotoxic agent Ara-C. Mice injected with cotreated tumor cells survived longer than mice challenged with Pam3CSK4 or Ara-C-treated cells. Administration of Pam3CSK4 or Ara-C reduced the tumor load of mice injected with tumor cells.
21041732Melanoma; Lung CarcinomaPromote immunityTumor growth inhibition after peritumoral administration of Pam(3)CSK(4) was restored in Kit(W-sh/W-sh) mice by local reconstitution with wild-type, but not TLR2-deficient, mast cells. Mast cells secrete multiple mediators after Pam(3)CSK(4) activation, and in vivo mast cell reconstitution studies also revealed that tumor growth inhibition required mast cell-derived IL-6, but not TNF. TLR2-activated mast cells also inhibited the growth of lung cancer cells in vivo.
20807806MelanomaPromote immunityTLR2-stimulated pmel CD8 T cells, but not TLR2(-/-)pmel or MyD88(-/-)pmel T cells, responded to significantly lower TAg levels and resulted in increased production of effector molecules and cytotoxicity. Wild-type or MyD88(-/-) mice treated with TLR2 ligand and pmel T cells, but not TLR2(-/-)pmel or MyD88(-/-)pmel T cells, showed tumor regression of an established melanoma tumor. Overexpressing TLR2 in TAg-specific T cells eradicated tumors; four times fewer cells were needed to generate antitumor responses. The enhanced antitumor activity of TLR2-MyD88-stimulated T cells was associated with increased effector function but perhaps more importantly with improved survival of T cells.
21421234Bladder CarcinomaPromote immunity (T cell function & infiltration); essential for immunotherapyTreatment with toll-like receptor 2 and 3 agonists showed the strongest inflammatory response in 2 primary cultures of normal urothelial cells and 3 bladder cancer cell lines. In cultured urothelial cells agonist inducible toll-like receptor 2 or constitutively expressed toll-like receptor 3 is functional. These data suggest the potential use of toll-like receptor agonists for antitumor immunotherapy of nonmuscle invasive tumors.
18587008B16 Malignant MelanomaPromote immunity (T cell function); increase the efficacy of immunotherapyRecent studies by several groups, including ours, have shown that TLRs can function as costimulatory receptors for antigen-specific T cells, resulting in enhanced T-cell survival and increased expression of effector molecules. These findings emphasize the physiological significance of TLR2 engagement on CTLs and could make possible new approaches for the development of effective immunotherapies by manipulating TLR signaling within CTLs.
22859216Hepatocellular CarcinomaPromote immunitySurprisingly, we found that the genetic deletion of TLR2 increased susceptibility to diethylnitrosamine (DEN), a genotoxic carcinogen that can induce HCC. Indeed, TLR2-deficient mice showed a significant increase in carcinogenesis and progression of HCC as indicated by increases in tumor nodule size, tumor volume, and animal death. We found that TLR2 deficiency caused a decrease in the infiltration of macrophages and an attenuation of apoptosis signal regulating kinase 1 (ASK1) / p38 mitogen-activated protein kinase (p38 MAPK) / nuclear factor kappa B (NF-κB) signaling, which led to a decrease in the expression of interferon-gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL)-1α/β, IL-6, and Cxcl-2 as well as suppression of autophagy flux and increases in oxidative stress and p62 aggregation in liver tissue. The defects in immune networks resulted in suppressed p21- and p16/pRb-dependent senescence, which caused an increase in proliferation and a decrease in apoptotic and autophagy-associated cell death in mouse livers.
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TLR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TLR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3040.501
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0430.429
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2390.81
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3940.358
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9820.591
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3530.883
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3270.498
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4430.747
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1730.911
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5730.222
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0360.293
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4890.000925
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TLR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TLR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TLR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TLR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TLR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TLR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TLR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTLR2
Nametoll-like receptor 2
Aliases TIL4; CD282; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4; CD antigen CD28 ......
Chromosomal Location4q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TLR2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TLR2.
ID Name Drug Type Targets #Targets
DB00045Lyme disease vaccine (recombinant OspA)BiotechTLR21
DB03963S-(Dimethylarsenic)CysteineSmall MoleculeCOPG1, NOS3, TLR2, XRCC44
DB05475GolotimodSmall MoleculeTLR2, TLR4, TLR7, TLR94
DB11601Tuberculin Purified Protein DerivativeBiotechTLR21